Nama's AI scorecard currently rates Cronos Group Buy (6.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is CRON's P/E ratio?

Cronos Group trades at a trailing price-to-earnings ratio of 10.6.

When does CRON report earnings?

Cronos Group's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.06.

What is the CRON price target?

The median analyst price target from 1 analysts is $2.99, with a range of $2.99 – $2.99.

Is CRON Shariah compliant?

Nama's AAOIFI-style screen reads Cronos Group as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Cronos Group (CRON)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Cronos Group (CRON) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $1.33B, a trailing price-to-earnings ratio of 10.6 and a free-cash-flow yield of 0.0%. Over the most recent reported fiscal year, revenue grew 24.6% and free cash flow per share fell 103.4%. Nama's AI scorecard rates it Buy, 6.2 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 6.2/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Leading · +31.2% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-46.8%

How far the last close sits under the highest price of the past five years.

Market cap	$1.33B
Trailing P/E	10.6
Price / book	1.2
Price / sales	7.4
FCF yield	0.0%
Dividend yield	—
Gross margin	47.9%
Operating margin	-2.0%
Net margin	19.1%
Revenue growth (YoY)	+24.6%
Revenue growth (3-yr annual)	+19.1%
EPS growth (YoY)	—
FCF/share growth (YoY)	-103.4%
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

CRON earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.06). Beat the EPS estimate in 3 of 3 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.06	$0.05	+20.0%	$63.45M
Q2 2026	Aug 6, 2026	$0.13	$0.01	+1200.0%	$53.01M
Q1 2026	May 11, 2026	$0.05	$0.01	+400.0%	$45.21M
Q3 2025	Nov 6, 2025	$0.10	—	—	$36.34M

CRON analyst price target

Median target $2.99 from 1 analysts, ranging $2.99 – $2.99.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live CRON data on Nama Insights →

CRON FAQ

Is CRON a buy?: Nama's AI scorecard currently rates Cronos Group Buy (6.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is CRON's P/E ratio?: Cronos Group trades at a trailing price-to-earnings ratio of 10.6.
When does CRON report earnings?: Cronos Group's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.06.
What is the CRON price target?: The median analyst price target from 1 analysts is $2.99, with a range of $2.99 – $2.99.
Is CRON Shariah compliant?: Nama's AAOIFI-style screen reads Cronos Group as Not Shariah Compliant. At least one of the three ratios or the industry test failed.